Brief: XORTX Therapeutics Announces Submission Of Clinical Trial Application To Conduct Bridging Pharmacokinetics Study
14/03/2022 11:22
March 14 (Reuters) - XORTX Therapeutics Inc XRTX.V :
* XORTX THERAPEUTICS ANNOUNCES SUBMISSION OF CLINICAL TRIAL
APPLICATION TO CONDUCT BRIDGING PHARMACOKINETICS STUDY
Source text for Eikon: ID:nGNX487Dpy
Further company coverage: XRTX.V
Recent news on XORTX Therapeutics
See all newsBrief: Xortx Outlines Anticipated Health Canada Clinical Trial Application For Xrx-026 For Gout
Brief: XORTX Therapeutics Announces Initiation Of Drug And Tablet Manufacturing For XRx-026 Program
Brief: Xortx Announces Termination And Postponement Of Investor Relations Program
Brief: XORTX Announces Director Resignation
Brief: Xortx Announces Us$5 Million Public Offering